| Worsening financial toxicity among patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: a mixed methods longitudinal study R Cusatis, I Tan, C Piehowski, I Akinola, E Crawford, J Craig, ... Blood 138, 567, 2021 | 9 | 2021 |
| Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T IM Akinola, R Cusatis, MC Pasquini, BE Shaw, V Bollu, A Dalal, ... Transplantation and cellular therapy 29 (4), 254. e1-254. e9, 2023 | 8 | 2023 |
| Role of molecular profiling of pancreatic cancer after neoadjuvant therapy: does it change practice? AN Krepline, L Bliss, J Geurts, I Akinola, KK Christians, B George, ... Journal of Gastrointestinal Surgery 24 (2), 235-242, 2020 | 8 | 2020 |
| A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis A D’Souza, A Szabo, I Akinola, M Finkel, KE Flynn Quality of Life Research 32 (6), 1807-1817, 2023 | 5 | 2023 |
| Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer AN Krepline, JL Geurts, I Akinola, KK Christians, CN Clarke, B George, ... HPB 22 (12), 1745-1752, 2020 | 3 | 2020 |
| Differences in patient‐reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis A D'Souza, A Szabo, I Akinola, M Finkel, KE Flynn European Journal of Haematology 111 (4), 536-543, 2023 | 1 | 2023 |
| Do PROs tell the whole story? Differential outcomes based on patient-reported outcomes (PROs) versus performance-based metrics (PBM) on cognition for patients receiving … I Tan, R Cusatis, E Crawford, A Thiengmany, C Piehowski, I Akinola, ... Blood 138, 3043, 2021 | 1 | 2021 |
| Patient-reported satisfaction with telemedicine in light chain (AL) amyloidosis care I Akinola, KE Flynn, A Szabo, M Finkel, A D’Souza Amyloid, 1-3, 2024 | | 2024 |
| Development and initial validation of the AL‐PROfile patient‐reported outcome measure in light chain (AL) amyloidosis A D'Souza, A Szabo, I Akinola, M Finkel, KE Flynn European Journal of Haematology, 2024 | | 2024 |
| HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice JE Thompson, Y Gao, A Visotcky, KE Flynn, M Mauro, E Giever, A Baim, ... Blood 142, 7420, 2023 | | 2023 |
| HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice M Mauro, EL Atallah, JE Thompson, Y Gao, A Visotcky, E Giever, A Baim, ... Blood 142, 7434, 2023 | | 2023 |
| Social Functioning after Transplantation and Cellular Therapy: Initial Patient-Reported Outcomes Results from the CIBMTR R Cusatis, E Ndifon, D Mattila, L Berman, I Akinola, M Kapfhammer, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | | 2023 |
| Impact on caregivers and families of patients receiving chimeric antigen receptor T-cell therapy: a prospective longitudinal mixed methods study C Litovich, C Piehowski, I Akinola, E Crawford, A D'Souza, M Frank, ... QUALITY OF LIFE RESEARCH 31, S145-S145, 2022 | | 2022 |
| Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving … I Tan, R Cusatis, E Crawford, A Thiengmany, C Piehowski, I Akinola, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| Chimeric Antigen Receptor t-Cell (CAR-T) Therapy Recipients and Worsening Financial Impact over Time: A Mixed Methods Longitudinal Study R Cusatis, I Tan, C Piehowski, I Akinola, E Crawford, J Craig, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| Role of neoadjuvant radiation in downstaging patients with localized pancreatic cancer–analysis of the ncdb database AN Krepline, CA Barnes, M Aldakkak, I Akinola, KK Christians, CN Clarke, ... HPB 21, S87-S88, 2019 | | 2019 |
